SteadyMed submits NDA for Trevyent to treat PAH

SteadyMed Ltd. (NASDAQ:STDY) submitted an NDA to FDA for Trevyent treprostinil to treat pulmonary arterial hypertension (PAH). The company hopes to launch the candidate in mid-2018.

SteadyMed partner Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said it expects to submit regulatory applications for the product in the EU and Canada by year end. In 2015, SteadyMed granted Cardiome exclusive rights to commercialize Trevyent in Europe, Canada and the Middle East (see BioCentury, Aug. 3, 2015)...